Policy & Regulation
First Patient Enrolled in Phase 2b Clinical Study to Evaluate the Efficacy and Safety of Ecopipam Tablets for the Treatment of Pediatric Patients with Tourette Syndrome
16 August 2019 - - The first patient was recently enrolled in US-based biopharmaceutical company Emalex Biosciences, Inc's international Phase 2b study to evaluate the efficacy and safety of ecopipam HCl tablets in children and adolescents with Tourette Syndrome, the company said.

Ecopipam is an investigational drug that selectively blocks the actions of dopamine at the D1 receptor.

The Phase 2b clinical study of ecopipam in children and adolescent patients (aged >6 to